Literature DB >> 16606961

Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices.

Joel Lexchin1.   

Abstract

Mesh：

Year:  2006        PMID： 16606961      PMCID： PMC1421463          DOI： 10.1503/cmaj.051687

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  1 in total

1.  "Me-too" products--friend or foe?

Authors:  Thomas H Lee
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245
  1 in total
  6 in total

1.  Rebuttal: are drugs too expensive in Canada?

Authors:  Joel Lexchin; Russell Williams; Jean Marion
Journal:  Can Fam Physician       Date:  2006-07       Impact factor: 3.275

2.  Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.

Authors:  Michael T Mueller; Alexander Frenzel
Journal:  Eur J Health Econ       Date:  2013-12-27

Review 3.  Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-02

4.  What is the value of 'me-too' drugs?

Authors:  Stephane Régnier
Journal:  Health Care Manag Sci       Date:  2013-02-26

5.  Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.

Authors:  Jacques LeLorier; Nugek S B Rawson
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

6.  Competition and price among brand-name drugs in the same class: A systematic review of the evidence.

Authors:  Ameet Sarpatwari; Jonathan DiBello; Marie Zakarian; Mehdi Najafzadeh; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2019-07-30       Impact factor: 11.069
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.